Form 4: Singular Genomics CFO Dalen Meeter Reports Stock Transactions

Sentiment:

SEC Form 4


Dalen Meeter, CFO of Singular Genomics Systems, Inc., reports the settlement of vested Restricted Stock Units (RSUs) resulting in the acquisition of 15,000 shares of Common Stock.

Summary

  • On May 9, 2024, Dalen Meeter, the Chief Financial Officer of Singular Genomics Systems, Inc. (OMIC), reported a transaction involving the settlement of vested Restricted Stock Units (RSUs).
  • This transaction resulted in the acquisition of 15,000 shares of Common Stock.
  • Following the reported transaction, Meeter beneficially owns 215,273 shares of Common Stock directly.
  • The RSUs vest in 16 equal quarterly installments over four years measured from February 9, 2024.
  • Meeter directly owns 225,000 derivative securities in the form of Restricted Stock Units.

Sentiment

Score: 5

Explanation: This is a neutral filing, simply reporting a routine transaction. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of the US market and are required by the SEC to provide transparency into the transactions of company insiders.

Key Dates

DateDescription
02/09/2024Date from which RSUs vest in 16 equal quarterly installments over four years.
05/09/2024Date of transaction involving the settlement of vested Restricted Stock Units (RSUs).
05/13/2024Date of signature of the report.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.